| pubmed-article:18037302 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18037302 | lifeskim:mentions | umls-concept:C2362561 | lld:lifeskim |
| pubmed-article:18037302 | lifeskim:mentions | umls-concept:C0007570 | lld:lifeskim |
| pubmed-article:18037302 | lifeskim:mentions | umls-concept:C0030956 | lld:lifeskim |
| pubmed-article:18037302 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:18037302 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:18037302 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:18037302 | lifeskim:mentions | umls-concept:C1332714 | lld:lifeskim |
| pubmed-article:18037302 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:18037302 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:18037302 | lifeskim:mentions | umls-concept:C0332256 | lld:lifeskim |
| pubmed-article:18037302 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:18037302 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:18037302 | pubmed:dateCreated | 2008-2-18 | lld:pubmed |
| pubmed-article:18037302 | pubmed:abstractText | Celiac disease is an intestinal disease caused by intolerance for gluten, a common protein in food. A life-long gluten-free diet is the only available treatment. As it is well established that the interaction between proline-rich gluten derived peptides and the human HLA-DQ2 molecules induces immune responses that lead to disease development, we have now designed a series of gluten peptides in which proline residues were replaced by azidoprolines. These peptides were found to bind to HLA-DQ2 with an affinity similar to that of the natural gluten peptide. Moreover, some of these peptides were found to be non-immunogenic and block gluten induced immune responses. These can thus serve as lead compounds for the development of HLA-DQ2 blocker peptides. | lld:pubmed |
| pubmed-article:18037302 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18037302 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037302 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18037302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037302 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037302 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18037302 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:18037302 | pubmed:issn | 1464-3391 | lld:pubmed |
| pubmed-article:18037302 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:18037302 | pubmed:author | pubmed-author:KoningFritsF | lld:pubmed |
| pubmed-article:18037302 | pubmed:author | pubmed-author:OverkleeftHer... | lld:pubmed |
| pubmed-article:18037302 | pubmed:author | pubmed-author:OverhandMarkM | lld:pubmed |
| pubmed-article:18037302 | pubmed:author | pubmed-author:WiesnerMartin... | lld:pubmed |
| pubmed-article:18037302 | pubmed:author | pubmed-author:KapoerchanVar... | lld:pubmed |
| pubmed-article:18037302 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18037302 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:18037302 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:18037302 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18037302 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18037302 | pubmed:pagination | 2053-62 | lld:pubmed |
| pubmed-article:18037302 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:18037302 | pubmed:meshHeading | pubmed-meshheading:18037302... | lld:pubmed |
| pubmed-article:18037302 | pubmed:meshHeading | pubmed-meshheading:18037302... | lld:pubmed |
| pubmed-article:18037302 | pubmed:meshHeading | pubmed-meshheading:18037302... | lld:pubmed |
| pubmed-article:18037302 | pubmed:meshHeading | pubmed-meshheading:18037302... | lld:pubmed |
| pubmed-article:18037302 | pubmed:meshHeading | pubmed-meshheading:18037302... | lld:pubmed |
| pubmed-article:18037302 | pubmed:meshHeading | pubmed-meshheading:18037302... | lld:pubmed |
| pubmed-article:18037302 | pubmed:meshHeading | pubmed-meshheading:18037302... | lld:pubmed |
| pubmed-article:18037302 | pubmed:meshHeading | pubmed-meshheading:18037302... | lld:pubmed |
| pubmed-article:18037302 | pubmed:meshHeading | pubmed-meshheading:18037302... | lld:pubmed |
| pubmed-article:18037302 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18037302 | pubmed:articleTitle | Design of azidoproline containing gluten peptides to suppress CD4+ T-cell responses associated with celiac disease. | lld:pubmed |
| pubmed-article:18037302 | pubmed:affiliation | Bioorganic Synthesis, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA, Leiden, The Netherlands. | lld:pubmed |
| pubmed-article:18037302 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18037302 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:18037302 | lld:chembl |
